Efficacy of tDCS on Pain in Multiple Sclerosis
Efficacy of tDCS on Pain Experience in People With Multiple Sclerosis: A Pilot Randomized Control Trial
We could not find results for this trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Real-tDCS + rehabilitation programme
Placebo
- Sham-tDCS + rehabilitation programme
What it measured
Main measures
Numeric Rating Scale (NRS)
4 weeks
Pain
Other measures (11)
Short Form McGill Pain Questionnaire (SF-MPQ)
1 week, 4 weeks, 8 weeks
PainBrief Pain Inventory (BPI)
1 week, 4 weeks, 8 weeks
Walking and mobilityPainMood and sleepPain Catastrophizing Scale (PCS)
1 week, 4 weeks, 8 weeks
PainCoping Strategies Questionnaire (CSQ)
1 week, 4 weeks, 8 weeks
PainBeck Depression Inventory II (BDI-II)
1 week, 4 weeks, 8 weeks
Mood and sleepMS Quality of Life - 54 (MSQOL-54)
1 week, 4 weeks, 8 weeks
Quality of life (reported by participants)Fatigue Severity Scale (FSS)
1 week, 4 weeks, 8 weeks
FatigueGo/No-go Task
1 week, 4 weeks, 8 weeks
Thinking and memoryPatient Global Impression of Change (PGIC)
1 week, 4 weeks, 8 weeks
Pressure Pain Threshold (PPT)
1 week, 4 weeks, 8 weeks
Pain
Who could take part
MS (type not specified) · 18 to 80
Show the full criteria
Inclusion criteria
* chronic pain defined as a constant or intermittent sensory symptom with unpleasant feelings or pain, lasting more than 3 months with a minimum score of 3 points on the Numeric Rating Scale (NRS) for pain perception; * lack of MS worsening in the three months just before the intervention period; * cognitive functioning to give informed consent identified by a Mini-Mental Status Examination (MMSE) score ≥ 24/30.
Exclusion criteria
* worsening of MS-related conditions or changes in drug therapy or any other confounding factor during the study; * rehabilitation treatments or Botulinum toxin injections during the three months preceding the start of the study; * intracranial metal implants that can be stimulated, incorrectly positioned, or overheated by the electric current; * severe cardiopulmonary, renal, and hepatic diseases; * pregnancy.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Pain is a common symptom experienced by people with MS and can significantly interfere with participation in the activities of daily living and adversely affect health-related quality of life. Pain in people with MS has the potential to become chronic, as a consequence of neuronal reorganization. Transcranial Direct Current Stimulation (tDCS) promotes the modulation of brain activity and its prolonged and continuous application can effect plastic modification. Combining tDCS with rehabilitation treatment may have effect in reducing pain in people with MS. This is a pilot randomized control trial to test the effects of tDCS in MS-related pain rehabilitation, its efficacy on pain (intensity, quality, interference with physical functioning), catastrophizing, emotional functioning and quality of life. Furthermore, we will explore the effects on pressure pain threshold and EEG recording. Correlations between sample characteristics and pain features will be investigated. Considering role of tDCS on neuropsychological functions, selective attention will be assessed.
Loading reviews and guidelines…
History
Started
Dec 2017
Main results due
Dec 2022
Finished
May 2023